Last reviewed · How we verify
Single-Dose IV Oritavancin Diphosphate
Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria.
Oritavancin diphosphate is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in Gram-positive bacteria. Used for Acute bacterial skin and skin structure infections (ABSSSI).
At a glance
| Generic name | Single-Dose IV Oritavancin Diphosphate |
|---|---|
| Also known as | Oritavancin Diphosphate |
| Sponsor | Melinta Therapeutics, Inc. |
| Drug class | Lipoglycopeptide antibiotic |
| Target | Lipid II |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Oritavancin diphosphate binds to the cell wall precursor lipid II, preventing the incorporation of D-alanyl-D-alanine into the cell wall, ultimately leading to cell lysis and death. This mechanism of action is specific to Gram-positive bacteria, making it effective against a range of pathogens, including MRSA.
Approved indications
- Acute bacterial skin and skin structure infections (ABSSSI)
Common side effects
- Nausea
- Vomiting
- Headache
- Infusion site reaction
Key clinical trials
- Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections (PHASE1)
- A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participants (PHASE1)
- Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers (PHASE1)
- Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects (PHASE1)
- Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I) (PHASE3)
- Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection (PHASE3)
- Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: